Zero deaths from tuberculosis: progress, reality, and hope

Zumla, Alimuddin; Kim, Peter; Maeurer, Markus; Schito, Marco

doi:10.1016/s1473-3099(13)70039-2

Cited by 13 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Attempts to eradicate this disease have been hampered by complex clinical presentation, delayed diagnosis, high rates of coincident HIV-1 infection, and rapid emergence of composite forms of drug resistance (1). Moreover, the 6-month TB treatment period is challenging for control programs of many countries with high incidences of the disease (2). In light of this, global research efforts are directed toward creating new treatment-shortening interventions and next-generation diagnostics, which collectively should result in more effective management of TB (3).…”

mentioning

confidence: 99%

Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with Tuberculosis

Chengalroyen

Beukes

Gordhan

et al. 2016

Am J Respir Crit Care Med

105

145

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with Tuberculosis

Chengalroyen

Beukes

Gordhan

et al. 2016

Am J Respir Crit Care Med

105

145

View full text Add to dashboard Cite

show abstract

“…DBS can bypass logistical issues http://ow.ly/otsFp Multidrug-and extensively drug-resistant (M/XDR) tuberculosis (TB) are emerging public health concerns [1,2]. In 2011, the World Health Organization (WHO) estimated 12 million prevalent cases of TB globally, which is equivalent to 170 cases per 100 000 population, out of these an estimated 630 000 cases were affected by MDR Mycobacterium tuberculosis strains [3].…”

mentioning

confidence: 99%

Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?

et al. 2013

View full text Add to dashboard Cite

@ERSpublications TDM can be helpful for multidrug-resistant tuberculosis therapeutic decisions. DBS can bypass logistical issues http://ow.ly/otsFp Multidrug-and extensively drug-resistant (M/XDR) tuberculosis (TB) are emerging public health concerns [1,2]. In 2011, the World Health Organization (WHO) estimated 12 million prevalent cases of TB globally, which is equivalent to 170 cases per 100 000 population, out of these an estimated 630 000 cases were affected by MDR Mycobacterium tuberculosis strains [3]. Among the newly diagnosed patients ,3.7% were infected by MDR-TB strains, but the worrisome fact is that the prevalence of MDR-TB among new cases in some Former Soviet Union countries exceeds 30% [4,5], XDR-TB has been identified in 84 countries and the average proportion of MDR-TB cases with an XDR-TB pattern is 9.0% [3]. Further adding to the problem are the reports of ''totally drug resistant'' TB [6,7], a term currently not recognised by WHO [8,9].Treatment of drug resistant TB is more expensive and more toxic if compared with that prescribed for drugsusceptible TB, and currently takes up to 2 years of therapy [10]. The cost per patient to treat MDR-TB cases is incredibly high [11,12] and, in spite of international public health efforts, the treatment outcome is not very promising [13][14][15]. DIEL et al. [16] showed that direct treatment-related costs of MDR-TB patients can amount to J52 259 in Germany (table 1).In the largest MDR-TB cohort analysed to date [13] the proportion of cases treated successfully was 62%, with 7% failing or relapsing, 9% dying and 17% defaulting; in the XDR-TB subgroup 40% achieved treatment success, 22% failed treatment or relapsed, whereas 15% died and 16% defaulted [14,15].In this issue of the European Respiratory Journal (ERJ) a Dutch group from Groningen [17] reported on the results of a prospective pharmacokinetic (PK) study aimed at quantifying the effect of clarithromycin on the exposure to linezolid. In simple terms they observed that clarithromycin, which has some activity against TB bacilli and is well tolerated, increases linezolid exposure (i.e. increases the blood levels of linezolid, which is a very expensive and toxic drug). The authors decided to quantify this phenomenon administering a fix dose of linezolid (300 mg twice a day) plus a variable one of clarithromycin (250-500 mg once a day).Using validated PK methods they demonstrated that linezolid exposure significantly increased after the coadministration of 500 mg clarithromycin by a median (interquartile range) of 44% (23-102%), when

show abstract

“…All these facts prompted re‐engineering and repositioning of old natural and synthetic bioactives for the development of fast acting new antitubercular drugs with novel mechanism of action to achieve effective TB control . Literature survey reveals that more efficacious new chemical entities can be envisaged by incorporating two or more highly active heterocyclic system into a single molecule .…”

Section: Introductionmentioning

confidence: 99%

“…All these facts prompted re-engineering and repositioning of old natural and synthetic bioactives for the development of fast acting new antitubercular drugs with novel mechanism of action to achieve effective TB control. [31][32][33][34] Literature survey reveals that more efficacious new chemical entities can be envisaged by incorporating two or more highly active heterocyclic system into a single molecule. [35] A rational approach for synthesis of bis heterocycles is envisaged by replacing pyridinyl ring of isoniazid with benzo [6,7]cyclohepta [1,2b]pyridine and incorporating the hydrazide fragment in the oxadiazole skeleton ( Figure 2).…”

Section: Introductionmentioning

confidence: 99%

Design, synthesis, and in vitro antituberculosis activity of benzo[6,7]cyclohepta[1,2‐b]pyridine‐1,3,4‐oxadiazole derivatives

et al. 2017

View full text Add to dashboard Cite

A new antitubercular agents, benzo[6,7]cyclohepta[1,2-b]pyridine-1,3,4- oxadiazole hybrids (6a-o), have been designed and synthesized involving oxidative cyclization of hydrazones by use of di(acetoxy)iodobenzene, characterized by IR, H NMR, C NMR, and HRMS, and further confirmed by X-ray analysis. All the newly synthesized compounds 4a-o evaluated for their in vitro antimycobacterial activity against Mycobacterium tuberculosis H37Rv (ATCC27294). Among the compounds tested, the compounds 4o (MIC: 1.56 μg/ml) and 4l, 4m (MIC: 3.125 μg/ml) are promising lead analogues and have shown lower cytotoxicity.

show abstract

Zero deaths from tuberculosis: progress, reality, and hope

Cited by 13 publications

References 6 publications

Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with Tuberculosis

Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with Tuberculosis

Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?

Design, synthesis, and in vitro antituberculosis activity of benzo[6,7]cyclohepta[1,2‐b]pyridine‐1,3,4‐oxadiazole derivatives

Contact Info

Product

Resources

About